The generic drug manufacturer announced fiscal 2019 results and inked an important supply deal.
These businesses offer the potential for above-average returns that could receive a huge helping hand from the power of compound interest.
The precious metal has been rising in price as global economic headwinds mount.
The company is flush with cash and wields a promising therapeutic pipeline. Is its recent tumble a buying opportunity?
The bad news keeps piling up.
China has decided that American oil exports, a relative strength in recent years, are fair game in the trade war.
The dog days of summer are finally behind us (on the calendar, anyway), but these three stocks offer sizzling growth potential.
Shares have been mired in a nearly continuous slide for the last year. Is Wall Street's pessimism misplaced?
Shares are trading hands at their highest level in years, and have posted a three-year return of over 350%.
Investors have run back to the stock after promising clinical results.
The business reported an operating loss of $77 million in the first nine months of fiscal 2019.
These income stocks can make your retirement funds go even further.
Inject a little (or a lot) of growth into your portfolio with these three companies.
The company has revised guidance in each of the last four quarters, but it continues to outperform expectations.
The clinical-stage biopharma announced changes to its lead pipeline program. Will it be enough?
Investors looking to grow their nest egg should give these three stocks a closer look.
The lab hardware company reported fiscal third-quarter 2019 operating results.
The gold miner delivered a solid performance in the first half of 2019, but investors are remaining cautious.
A sluggish end to fiscal 2019 and weaker-than-expected guidance for the year ahead aren't instilling much confidence in investors.
The genetic testing company reported fiscal 2019 operating results and told investors that regulators want changes to an important product.